📊 Zydus Lifesciences – Technical & Fundamental View

Technical Outlook: Zydus has been in a steady uptrend since March, consistently forming higher highs and higher lows. The stock is currently trading above its 20/50-day EMAs (~₹1,008/₹995), indicating strong momentum. RSI at ~66 reflects bullish strength, still below the overbought zone. Immediate resistance is seen around ₹1,060–₹1,080; a breakout above this may push the stock towards ₹1,120–₹1,150. On the downside, support lies at ₹995–₹1,000, followed by ₹970 Fundamental Outlook: Zydus Lifesciences has shown robust performance, driven by strong growth in its US generics portfolio and steady India formulations business. Its launch pipeline in injectables, specialty products, and biosimilars continues to add visibility. The company reported healthy revenue growth in Q1FY26 with expanding margins supported by cost efficiencies and product mix improvement. Focus on innovation, expansion in emerging markets, and a healthy balance sheet position Zydus well for long-term growth. Short-Term View: Positive; potential to test ₹1,060–₹1,080 with stop loss at ₹995. Long-Term View: Bullish; strong US portfolio, specialty pipeline, and domestic market growth could drive the stock towards ₹1,150–₹1,200 over the next 12–18 months. ⚠️ Risks: USFDA regulatory actions, pricing pressure in generics, and currency volatility remain key watch factors.